I thought you were always hoping Mesoblast would get a product into revenue generation stage ... this offers a path, but you sound unhappy about this outcome as always. Would you rather they give away half the future cash flows from the program and partner pediatric aGVHD?
This outcome is non-dilutive and will fund the program to launch and revenue generation in 2019.
Partnerships for CHF and adult aGVHD, RA and CLBP still in play.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.